Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx is a leader in delivering customized electronic pharma messages to healthcare providers, and its differentiated ability to deliver three types of messages in the provider's EHR sets it apart from the competition. With its new programmatic connection and strong growth drivers, coupled with its impressive ability to expand margins, OptimizeRx is poised for double-digit revenue growth and continued profitability.

Bears say

OptimizeRx is expected to face continued headwinds due to macroeconomic risks and the company-specific execution issue caused by one of their top clients. Although the company has maintained their EBITDA outlook through cost actions, its organic total revenue has declined in the past few years. With 2026 revenue guidance being lowered by 13%, the company's reliance on drug approvals by FDA and its customer concentration pose additional risks. Also, the recent announcement of allowing DSPs access to their EHR network may provide incremental revenue, but the financial contribution and sizing remain uncertain. The company's 4Q25 results showed modest revenue growth, but its organic total revenue has been negative in recent years and its net revenue retention has also declined. Despite the positive gross margin outperformance and lower operating expenses, the company's future visibility is challenged due to the current headcount being able to support a lower revenue run-rate and contracted revenue being lower than historical visibility. Even though AI could potentially provide a tailwind, its impact on the financials remains unknown, and the company has not provided specific NRR guidance. Overall, given the various risks and uncertainties, OptimizeRx's stock may continue to underperform in the near term.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.